Skip to main content
SpringerLink
Log in

G4 European countries can expect higher health care costs following generic substitution of topiramate, based on the Canadian experience

  • Epidemiology clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.The impact of generic substitution of topiramate on health care costs: conversion of the Canadian experience into the settings of G4 European countries. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research: 191 abstr. PND8, 16 May 2009. Available from: URL: http://www3.interscience.wiley.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

G4 European countries can expect higher health care costs following generic substitution of topiramate, based on the Canadian experience. Pharmacoecon. Outcomes News 579, 6 (2009). https://doi.org/10.2165/00151234-200905790-00011

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905790-00011

Keywords

Search

Navigation